Orion OYJ (OTCMKTS:ORINY) Announces Quarterly Earnings Results

Orion OYJ (OTCMKTS:ORINY) announced its quarterly earnings data on Wednesday. The company reported $0.68 earnings per share for the quarter, Zacks reports. Orion OYJ had a net margin of 28.52% and a return on equity of 50.37%. The business had revenue of $623.96 million for the quarter.

Orion OYJ Stock Performance

OTCMKTS:ORINY remained flat at $54.00 during mid-day trading on Thursday. The company’s stock had a trading volume of 948 shares, compared to its average volume of 1,259. Orion OYJ has a fifty-two week low of $30.89 and a fifty-two week high of $56.05. The company has a current ratio of 2.64, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08. The firm’s 50-day simple moving average is $47.37 and its two-hundred day simple moving average is $41.45. The stock has a market capitalization of $15.24 billion, a PE ratio of 22.22 and a beta of 0.07.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group upgraded Orion OYJ from a “hold” rating to a “strong-buy” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Orion OYJ presently has an average rating of “Buy”.

About Orion OYJ

Orion Oyj, also known as Orion Corporation, is a Finnish pharmaceutical company that develops, manufactures and markets human and veterinary medicines. Its portfolio includes prescription medicines, over-the-counter products, generic pharmaceuticals and active pharmaceutical ingredients.

The company focuses on several therapeutic areas, including central nervous system disorders, oncology, respiratory diseases, pain management and veterinary medicine. Orion is particularly recognized for treatments related to Parkinson’s disease, as well as its Easyhaler line of inhaled medicines for respiratory conditions.

Founded in Finland in 1917, Orion is headquartered in Espoo.